M.D. Ph.D. David D. Chang - 24 Jan 2025 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
President and CEO, Director
Signature
/s/Earl Douglas, Attorney-in-Fact
Issuer symbol
ALLO
Transactions as of
24 Jan 2025
Net transactions value
$0
Form type
4
Filing time
28 Jan 2025, 20:10:50 UTC
Previous filing
20 May 2024
Next filing
05 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Award $0 +552,174 +11% $0.000000 5,363,240 24 Jan 2025 Direct F1
holding ALLO Common Stock 856,044 24 Jan 2025 See footnote F2
holding ALLO Common Stock 856,044 24 Jan 2025 See footnote F3
holding ALLO Common Stock 1,201,108 24 Jan 2025 See footnote F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALLO Stock Option (Right to buy) Award $0 +1,952,130 $0.000000 1,952,130 24 Jan 2025 Common Stock 1,952,130 $1.94 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 960 shares of the Issuer's common stock acquired by the reporting person on September 15, 2024 pursuant to an employee stock purchase program.
F2 Securities held in the name of the RTC 2019 Trust dated October 1, 2019.
F3 Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
F4 Securities held in the name of the Chang 2006 Family Trust
F5 25% of the shares subject to the stock option shall vest on January 24, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter.

Remarks:

Exhibits: Power of Attorney